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Carcinoma of the stomach remains a major cause of death in most
Western countries. The only proven effective therapy is surgery,
but overall 5-year survival rates remain low after resection. In
1981, the Japanese Society for Research in Gastric Cancer
(JSRGC) standardized the gastric resections and the extent of
regional lymphadenectomy in accordance with specific rules
(updated over the years) based on the location of the tumour and
the respective regional node drainage (Kajitani, 1981). Large
retrospective series from Japan of radical gastrectomy with level-2
extended lymphadenectomy (D2 resections) have shown impres-
sive 5-year survival rates, certainly much higher than experienced
in the West (Mine et al, 1970; Miwa, 1979; Maruyama et al, 1987;
Nakajima and Nishi, 1989). Some non-Japanese centres have also
reported favourably on D2 resections (Smith et al, 1991; Jaehne et
al, 1992; Siewert et al, 1993; Sue-Ling et al, 1993; Mendes et al,
1994). However, the benefit of D2 over conventional D1 resections
(where only the perigastric nodes within 3.0 cm of the primary are
removed) had not been tested prospectively until the launch of the
Medical Research Council (MRC) Gastric Cancer Surgical Trial
(ST01) in 1986. This was a randomized comparison of D1 versus
D2 resections for potentially curable advanced gastric cancer. At
the time the study was formulated, the Japanese rules dictated that
pancreatico-splenectomy was an integral part of D2 resection for
all tumours except antral cancers. For this reason en-bloc removal
of these two organs with the stomach was specified by the MRC
ST01 trial protocol for middle and upper third tumours in the D2
arm. In this paper, we report on the long-term outcome of these
two surgical treatment arms. Preliminary results of ST01
(Cuschieri et al, 1996), and a similar Dutch trial (Bonenkamp et al,
1995), have shown that splenectomy and distal hemi-pancreatec-
tomy are attended by a significant increase in post-operative
morbidity and mortality. The influence of removal of these organs
on long-term survival is addressed in this analysis. This is impor-
tant as distal hemi-pancreatectomy is no longer considered an inte-
gral part of D2 resections by Japanese surgeons, and some Western
centres are practising spleen- and pancreas-preserving D2 resec-
tions with apparent good results (Sue-Ling et al, 1993; Griffith,
1995), despite the reported splenic hilar lymph nodes involvement
in 15–27% of gastric cancers (Fass and Schumpelick, 1989;
Mendes et al, 1994; Mendes et al, 1995; Tsuburaya et al, 1995).
PATIENTS AND METHODS
The organization and preliminary results of the MRC ST01 trial are
summarized briefly since they have been reported previously
(Cuschieri et al, 1996). Patients enrolled in MRC ST01 were to
have histologically proven, and potentially curable, gastric carci-
noma. Patients were excluded if they were young (< 20 years), had
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Summary Controversy still exists on the optimal surgical resection for potentially curable gastric cancer. Much better long-term survival has
been reported in retrospective/non-randomized studies with D2 resections that involve a radical extended regional lymphadenectomy than
with the standard D1 resections. In this paper we report the long-term survival of patients entered into a randomized study, with follow-up to
death or 3 years in 96% of patients and a median follow-up of 6.5 years. In this prospective trial D1 resection (removal of regional perigastric
nodes) was compared with D2 resection (extended lymphadenectomy to include level 1 and 2 regional nodes). Central randomization followed
a staging laparotomy.
Out of 737 patients with histologically proven gastric adenocarcinoma registered, 337 patients were ineligible by staging laparotomy
because of advanced disease and 400 were randomized. The 5-year survival rates were 35% for D1 resection and 33% for D2 resection
(difference –2%, 95% CI = –12%–8%). There was no difference in the overall 5-year survival between the two arms (HR = 1.10, 95% CI
0.87–1.39, where HR > 1 implies a survival benefit to D1 surgery). Survival based on death from gastric cancer as the event was similar in the
D1 and D2 groups (HR = 1.05, 95% CI 0.79–1.39) as was recurrence-free survival (HR = 1.03, 95% CI 0.82–1.29). In a multivariate analysis,
clinical stages II and III, old age, male sex and removal of spleen and pancreas were independently associated with poor survival. These
findings indicate that the classical Japanese D2 resection offers no survival advantage over D1 surgery. However, the possibility that D2
resection without pancreatico-splenectomy may be better than standard D1 resection cannot be dismissed by the results of this trial.
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undergone gastric surgery, harboured a co-existing cancer or had
serious co-morbid cardiorespiratory disease that would preclude a
safe D2 resection. All patients underwent staging laparotomy to
define potentially curative disease. Eligible cases were those that
fell within the UICC TNM cancer stages I–III (Sobin and
Wittekind, 1997). Tumour stage was determined by pathology of
the resected specimens. The patients were randomized centrally
(over the telephone), within the same operating session, to either D1
or D2 gastrectomy. In total, 400 eligible patients were randomized.
The operative details of the two arms were defined in terms of
the extent of gastric resection, the macroscopic tumour-free
margins and the level of lymphadenectomy (N1 or N2). D1 resec-
tions entailed removal of the lymph nodes within 3.0 cm of the
tumour (considered N1 in TNM system) en bloc with the greater
omentum and stomach. D2 resections necessitated the additional
removal of the omental bursa, the hepatoduodenal and retro-
duodenal nodes (antral lesions) and the splenic artery/splenic hilar
nodes and retropancreatic nodes by distal hemipancreatico-
splenectomy for middle and upper third lesions. In both arms, a
distal gastrectomy up to and including the duodenal bulb with a
minimum of 2.5 cm proximal tumour-free margin was performed
for antral neoplasms, whereas total gastrectomy was undertaken
for middle and proximal tumours.
D2 resections were followed by a significantly higher morbidity
and mortality than D1 resections; this was attributable on subset
analysis to the pancreatico-splenectomy that was largely confined
to the D2 arm (Cuschieri et al, 1996). Patients were followed up at
regular intervals. Complete follow-up was available to death or 3
years in 96% of patients, and the median follow-up time was
6.5 years. Patients were followed up through the participating
surgeon, their General Practitioner (GP) or via the Office for
National Statistics.
Statistical methods
Eligible patients were randomized centrally by use of random
permuted blocks, and with stratification for centre, nodal status
and tumour location (antral, middle, proximal, total, mixed).
Sample size calculations were based on a pre-study survey of 26
gastric surgeons, which indicated that the baseline 5-year survival
rate of D1 surgery was expected to be 20%, and improvement in
survival to 34% (14% change) with D2 resection would be a real-
istic expectation. Thus 400 patients (200 in each arm) were to be
randomized, providing 90% power to detect such a difference with
P < 0.05.
The analysis of the trial has been performed on an intention-to-
treat basis. The statistical analysis was conducted using the SPSS
software system. Univariate survival analyses were performed
using the Kaplan–Meier method, and treatment comparisons were
made with the log-rank test. Cox’s proportional hazards technique
was used to fit the multivariate survival model. Significant prog-
nostic factors were chosen using a forward stepwise method.
RESULTS
The trial profile is shown in Figure 1. In total, 737 patients with
histologically proven gastric adenocarcinoma were registered from
32 surgeons in 7 years. Of these, 337 patients were found to be inel-
igible at staging laparotomy, which confirmed disease at a more
advanced stage than that specified in the protocol. Thus 400 eligible
patients were randomized, and all were available for analysis,
although stage could not be ascertained for 25 patients due to
missing pathology data. Their characteristics are shown in Table 1.
Overall survival
The overall 5-year survival rate for both arms is 34% (95% confi-
dence interval (CI) 29–39%).
Survival by allocated treatment
Survival ‘on an intention-to-treat basis’ in the two randomized
arms of the trial is shown in Figure 2. D2 resection offers no signif-
icant survival benefit over D1 surgery (log-rank statistic = 0.63 on
1 degree of freedom (df), P = 0.43; hazard ratio (HR) = 1.10, 95%
CI 0.87–1.39). The 5-year survival rates are 35% for D1 resection
and 33% for D2 resection. Hence the absolute difference in 5-year
survival is –2%, and the 95% confidence interval (–12% to 8%)
excludes a 5-year survival benefit of more than 8% to D2 resection.
The higher post-operative mortality in the D2 arm can be seen by
the early dip in the survival curve. It had been thought that
improved long-term survival in the D2 arm would compensate for
the higher early mortality. However, this does not appear to be the
case and the curves have not crossed after 7 years. Survival has
also been examined with death from gastric cancer as the event
(Figure 3A), post-operative deaths have been censored. Again,
there is no benefit to D2 surgery (log-rank statistic = 0.12 on 1 df,
P = 0.72; HR = 1.05, 95% CI 0.79–1.39). The lack of the early dip
in the D2 curve is due to censoring of the post-operative deaths.
Similarly, we observed no difference in recurrence-free survival
(Figure 3B) between the D1 and D2 groups (log-rank statistic =
0.072 on 1 df, P = 0.79; HR = 1.03, 95% CI 0.82–1.29).
Survival by lymphadenectomy
Within the context of this study, extent of lymphadenectomy can be
interpreted as representing ‘received’ treatment. There is evidence
Patients randomized (n=400)
Staging laparotomy (n=737) Ineligible (n=337)
D1 surgery (n=200) D2 surgery (n=200)
Followed up (n=200) Followed up (n=200)
Died (n=137) Died (n=144)
Followed up for ³ 3 years (n=190) Followed up for ³ 3 years (n=197)
Followed up for ³ 5 years (n=172) Followed up for ³ 5 years (n=186)
Patients Registered (n=737)
Figure 1 Trial profile of MRC ST011524 A Cuschieri et al
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from the Dutch trial for ‘non-compliance or contamination’ in the
extent of lymphadenectomy performed in the two randomized arms
(Bunt et al, 1994). This has occurred in the MRC study as indicated
in Table 2, which outlines nodal involvement by location and treat-
ment. The percentage of patients in both arms with involvement of
the nodal groups (Table 3) sheds some light on the existing contro-
versies. In the first instance it shows the limited gain in terms of
radicality of inclusion of distal pancreatectomy in gastric resections
for cancer. Secondly, it documents the widespread nodal involve-
ment in diffuse CMA lesions and, thirdly, it cautions against splenic
conservation in proximal tumours.
If a radical lymphadenectomy had been done in accordance with
the Japanese rules (Kajitani, 1981), all D2 patients should have had
resection of the anterior hepatic nodes (group 8a nodes). Local
pathology data are available in 191 D2 patients of whom 95 had
documented harvest of these nodes. Survival analysis for D1 vs
D2 (hepatic nodes not resected) vs D2 (hepatic nodes resected)
showed no significant difference (log-rank statistic = 0.91 on 2 df,
P = 0.63).
Evaluation of the number of lymph nodes removed is used by
the Japanese as a quality control of the extent of lymphadenec-
tomy. The median number of lymph nodes sampled were 13 in the
D1 arm and 17 in the D2 arm. Significantly more nodes were
sampled in the D2 arm (large scale normal approximation to the
Mann–Whitney U-test, statistic = –3.98, P < 0.001). According to
the Japanese rules, a radical lymphadenectomy corresponding to a
D2 resection is defined as extirpation of 26 or more nodes
(Kajitani, 1981). Of the 375 patients for whom nodal sampling
data was available, 310 (165 in the D1 arm, 145 D2) had < 26 nodes
and 65 (19 D1, 46 D2) had 26 or more nodes harvested from the
specimen by the local pathologist. The survival of these two
cohorts of patients was not significantly different (HR = 1.00, 95%
CI 0.73–1.37).
Effect of splenectomy and pancreatico-splenectomy on
survival
Table 4 shows the number of patients for each treatment, and
tumour location for the patients who had splenectomy only,
pancreatico-splenectomy, or neither of these organs removed. No
patients had a distal hemipancreatectomy without a splenectomy.
Splenectomy was performed in 54 (27%) patients allocated to D1
surgery, the majority (n = 37) because of proximal location of the
tumour to the spleen where the surgeon considered splenectomy to
Table 1 Patient characteristics
D1 surgery D2 surgery Total
n (%) 5-year n (%) 5-year n (%) 5-year
survival(%) survival (%) survival (%)
Total 200 35 200 33 400 34
Sex
Male 132 (66) 29 138 (69) 28 270 (67) 29
Female 68 (34) 45 62 (31) 44 130 (33) 45
Age
< 60 45 (23) 54 54 (27) 47 99 (25) 50
60–69 78 (39) 31 61 (30) 27 139 (35) 29
70 + 77 (38) 28 85 (43) 29 162 (40) 29
Location
C, CM 65 (33) 24 57 (29) 17 122 (31) 21
M, MC, MA 31 (15) 45 45 (22) 36 76 (19) 40
A, AM 91 (46) 40 94 (47) 43 185 (46) 42
CMA 13 (6) 29 4 (2) 0 17 (4) 22
Spleen or pancreas removed?
Neither removed 138 (69) 35 69 (35) 46 207 (52) 39
Spleen removed 54 (27) 39 18 (9) 33 72 (18) 38
Both removed 8 (4) 13 113 (56) 25 121 (30) 24
Tumour stage
T1 48 (25) 77 40 (21) 67 88 (22) 72
T2 63 (32) 38 69 (35) 32 132 (34) 35
T3 84 (43) 11 86 (44) 17 170 (44) 15
Missing 5 5 10
Nodal status
N0 69 (38) 63 78 (41) 51 147 (39) 56
N1 76 (41) 16 61 (32) 25 137 (36) 20
N2 39 (21) 21 53 (27) 13 92 (25) 17
Missing 16 8 24
Clinical stage
I 67 (36) 69 63 (33) 58 130 (35) 64
II 37 (20) 22 53 (28) 31 90 (24) 28
III 80 (44) 11 75 (39) 11 155 (41) 11
Missing 16 9 25D1 and D2 resections for gastric cancer 1525
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be necessary. However, seven patients with A, AM tumours also
had splenectomy (two for iatrogenic laceration, no reason docu-
mented for the others). Four patients in the D1 arm with C, CM
lesions had pancreatico-splenectomy. In all instances, this was
because of adherence of tumour to the pancreas. In the D2 arm, the
patterns of splenic and pancreatic resection reflect the specifica-
tions of the protocol, except that 24 patients with A, AM lesions
had pancreatico-splenectomy.
Figure 4 shows the survival split for three groups: those with
pancreatico-splenectomy (predominantly D2), those with removal
of spleen but with preservation of pancreas and those with neither
organ removed. There is a significant survival difference between
the three groups (log-rank statistic = 9.12 on 2 df, P = 0.0104). The
pancreatico-splenectomy group had the poorest survival. This
adverse effect of pancreatico-splenectomy may be interpreted in
light of the lack of benefit to D2 surgery shown by Figures 2 and 3.
Since 57% of the D2 arm had pancreatico-splenectomy compared
to 4% in the D1 arm, survival of D2 patients who did not have the
pancreas removed ought to be better than the corresponding D1
patients to pull the overall curves together. This assumption
appears to be strengthened by the survival curve by treatment and
splenectomy with or without pancreatectomy (Figure 5). However,
the inference that D2 surgery is superior to D1 in this group of
patients has to be made cautiously because of the confounding
influence of other variables.
Multivariate analysis
This was undertaken to establish whether splenectomy and pancre-
atico-splenectomy have an important effect on survival in the
presence of other prognostic factors. For example, patients who
received D2 surgery without spleen or pancreas removal had better
survival than the corresponding D1 group (Figure 5). However,
virtually all of these D2 patients had antral tumours, so it could be
argued that tumour location is the factor that affects their survival.
The prognostic variables fitted into the model were age, sex,
treatment, location of tumour, tumour stage, nodal status, clinical
stage, and level of resection of spleen and pancreas. Using a
forward stepwise selection procedure, clinical stage, age, sex, and
level of resection of spleen and pancreas were found to have a
significant influence on survival. The hazard ratios and 95% confi-
dence intervals in the final model are shown in Table 5. Older
patients, males and stage II or III patients all experience poor
survival. Patients who underwent pancreatico-splenectomy have
significantly worse survival than those who had neither organ
resected, but the hazard ratios for patients who had spleen alone
resected, over those who had neither, falls just short of signifi-
cance at the 5% level.
It is worth noting that treatment is not an important factor in this
model. If it is added to the model, it has a hazard ratio of 0.93
(95% CI 0.68–1.26). However, in the protocol, pancreatico-
splenectomy is specified for the majority of D2, but not D1,
patients. This analysis thus shows the effect not of allocated treat-
ment but of an ‘idealized’ comparison of D1 with D2, with no
imbalance in the proportion of patients undergoing pancreatico-
splenectomy.
There is a possibility that nodal status was unbalanced in this trial
by the greater nodal sampling in the D2 arm. This would also affect
clinical stage. To examine the possible effect of unbalanced nodal
status, clinical stage, the multivariate analysis was run without
nodal or clinical stage. The resulting model was similar, with
































































Figure 2 Survival by treatment1526 A Cuschieri et al
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stage. If allocated treatment is added into this model, its hazard ratio
is 0.88 (95% CI 0.65–1.20). This is similar to the model with clin-
ical stage, implying that interpretation of any potential treatment
effect is not greatly affected by inclusion of clinical stage.
It has been suggested that location of the tumour might have
an important effect on survival since location, and level of spleen
and pancreas resection are strongly linked. For this reason, the

















































































































































Figure 3 (A) Survival by treatment with death from gastric cancer as the event. (B) Recurrence-free survivalD1 and D2 resections for gastric cancer 1527
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Table 2 Examination (by local pathologist) and involvement of nodes by location of primary and treatment
D1 surgery D2 surgery
C, M, A, CMA C, M, A, CMA
CM MC, AM CM MC, AMa
MA MA
Total number of patients 64 31 91 13 57 45 94 4
Cardiac nodes
Examined 39 17 14 7 33 17 15a 2
Involved 16 3 2 4 22 2 4 1
Greater and lesser curve nodes
Examined 56 28 83 9 52 38 84 4
Involved 31 10 39 7 29 16 43 3
Supra and infra pyloric nodes
Examined 32 19 59 8 27 21 61 3
Involved 4 4 32 4 5 6 25 0
Left gastric nodes
Examined 33 15 34 7 41 21 62 3
Involved 17 3 11 4 23 4 16 1
Splenic nodes
Examined 16 7 6 4 32 20 19 2
Involved 5 1 0 3 7 3 0 0
Hepatic nodes
Examined 1 3 9 0 28 22 42 3
Involved 0 1 3 0 4 3 4 1
Coeliac nodes
Examined 10 1 9 1 33 19 42 3
Involved 4 0 2 0 11 4 8 1
Hepato-duodenal nodes
Examined 4 0 7 1 12 16 29 1
Involved 0 0 5 1 1 1 3 0
Retropancreatic nodes
Examined 4 0 2 0 17 19 15 3
Involved 0 0 1 0 2 4 2 0
Distant nodesb
Examined 18 3 21 5 14 14 20 1
Involved 3 0 1 1 1 1 2 0
D1 = 199 gastric adenoca + 1 lymphoma. aNodes removed in patients with large tumours involving the antrum and middle third. bNodes retrieved from resected
specimen > N2 with respect to location of primary.
Table 3 Percentage of patients in both D1 and D2 arms with nodal involvement by location of tumour
C, CM CMA M, MC, MA A, AMb
Total number of patients 122 17 76 185
Cardiac nodes 53a (38/72) 56a (5/9) 15 (5/34) 20 (6/29)b
Greater & lesser curve nodes 56a (60/108) 77a (10/13) 39a (26/66) 49a (82/167)
Supra & infra pyloric nodes 15 (9/59) 36a (4/11) 25a (10/40) 48a (57/120)
Left gastric nodes 54a (40/74) 50a (5/10) 19 (7/36) 28a (27/96)
Splenic nodes 25a (12/48) 50a (3/6) 15 (4/27) –
Hepatic nodes 14 (4/29) 33a (1/3) 16 (4/25) 14 (7/51)
Coeliac nodes 35a (15/43) 25a (1/4) 20 (1/4) 20 (10/51)
Hepato-duodenal nodes 6 (1/16) 50a (1/2) 6 (1/16) 22 (8/36)
Retro-pancreatic nodes 10 (2/21) – 21 (4/19) 18 (3/17)
Distant  nodesc 13 (4/32) 17 (1/6) 6 (1/17) 7 (3/41)
a³ 1:4 patients with nodal group involvement. bCardiac nodes removed in patients with large tumours involving the antrum and middle third. cNodes retrieved
from resected specimen > N2 with respect to location of primary.1528 A Cuschieri et al
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investigated. Adding tumour location does not greatly alter the
hazard ratio for splenectomy alone (HR = 1.23) and for pancre-
atico-splenectomy (HR = 1.47), and the estimate of treatment
effect (HR = 0.96) does not change significantly.
DISCUSSION
This trial has shown that there is no difference in long-term
survival between D1 and D2 surgery equivalent to the Japanese D2
resection as defined by JRSGC involving pancreatico-splenec-
tomy for middle and proximal third tumours. It could be argued
that the D1 resection (based on TNM system, i.e. removal of lymph
nodes within a 3.0 cm radius of the primary) in this trial did not
conform with the strict definition of the JRSGC (removal of N1
lymph nodes in accordance with location of primary). In essence,
however, these are equivalent in terms of the nodal harvest,
although some argue that the TNM-based D1 resection removes
more nodes than the Japanese equivalent. There are no compara-
tive trials to confirm this view. The other problem inherent to all
surgical trials has been ‘contamination and non-compliance’. In
the MRC study we relied on individual responsibility of the partic-
ipating surgeons who were shown videos of the procedures and
had agreed to undertake the two surgical options, highlighted in a
booklet designed for the study. Quality control could only be
Table 4 Spleen and pancreas removal by location and treatment
Treatment Tumour Spleen/pancreas removed?
arm location
Neither removed Splenectomy only Pancreatico-splenectomy
Count (%) Count (%) Count (%)
D1 surgery
C, CM 33 (51) 28 (43) 4 (6)
M, MC, MA 19 (61) 10 (32) 2 (7)
A, AM 83 (91) 7 (8) 1 (1)
CMA 3 (23) 9 (69) 1 (8)
Total 138 (69) 54 (27) 8 (4)
D2 surgery
C, CM 1 (2) 7 (12) 49 (86)
M, MC, MA 2 (4) 7 (16) 36 (80)
A, AM 66 (70) 4 (4) 24 (26)
CMA 0 (0) 0 (0) 4 (100)



















































































Figure 4 Survival by spleen and pancreas removalD1 and D2 resections for gastric cancer 1529
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assessed by the operative data forms (site of tumour, extent of
gastric resection, resection margins, lymph node harvest) and the
pathological examination of the resected specimens with respect to
location of the tumour. Supervision of the surgeons in the oper-
ating room was not possible. Despite this obvious limitation, the
problem of contamination and non-compliance does not appear to
be greater than that encountered in the Dutch study (Bunt et al,
1994) where an experienced Japanese surgeon proctored the
participating surgeons for some time.
The mortality reported for the D1 and D2 arms of the MRC ST01
study is virtually identical to that of the equivalent Dutch trial, but
undoubtedly higher than that reported by the Japanese (Mine et al,
1970; Miwa, 1979; Maruyama et al, 1987; Nakajima and Nishi,
1989) and some Western centres (Smith et al, 1991; Jaehne et al,
1992; Siewert et al, 1993; Sue-Ling et al, 1993; Mendes et al,
1994). Whilst factors such as experience born of sustained case-
load, surgical skill, quality of post-operative care and case selec-
tion are important, it is not possible to make valid comparisons on
mortality between published series without data on pre-operative
risk stratification of the patients. Subset analysis of the surgeons’
results in the ST01 study showed no effect of caseload (number of
patients entered) on post-operative mortality.
The other main conclusion reached is that pancreatico-splenec-
tomy should not form a routine part of D2 resections. Pancreatico-
splenectomy appears to disadvantage these patients, both in terms
of increased post-operative morbidity and mortality and, probably,
by reducing long-term survival. Undoubtedly, the high proportion
of pancreatico-splenectomies in the D2 arm must have adversely
affected the overall survival rate of D2 patients. Hence D2 surgery
without pancreatico-splenectomy may carry better survival rates
than D1 resection, but this inference must be tested by a further
randomized study. It is difficult to untangle the adverse effects of
splenectomy from those of pancreatectomy on the survival of
patients in this trial but the multivariate analysis suggests that
pancreatic resection has the stronger effect. The recommendation
is, therefore, that pancreatic resection should only be performed in
D2 resections if there is direct extension of disease to the pancreas
from posteriorly situated tumours. Preservation of the pancreas is
now being recommended and practised by Japanese surgeons in D2
resections for gastric cancer (Otsuji et al, 1997).
It is difficult to reach any definite conclusions on the influence
of the extent of lymphadenectomy on long-term survival. The
comparison in the present trial between radical lymphadenectomy,






































































































Figure 5 Survival by treatment with spleen and distal pancreas removed or not removed
Table 5 Hazards ratios and 95% CIs for the fitted multivariate model
Variable Hazard ratio 95% CI P-value
Clinical stage
I 1.0
II 2.19 1.54–3.12 < 0.0001
III 3.87 2.83–5.28 < 0.0001
Age 1.03 1.01–1.04 0.0001
Sex
Male 1.0
Female 0.62 0.48–0.81 0.0005
Spleen/pancreas resection
Neither resected 1.0
Splenectomy only 1.36 0.97–1.90 0.0716
Pancreatico-splenectomy 1.53 1.17–2.01 0.00201530 A Cuschieri et al
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25 or fewer regional nodes suggests no difference but it must be
stressed that this analysis was conducted on non-randomized data.
In the German prospective, but non-randomized, study where the
surgeons were allowed to perform their preferred resection, radical
lymphadenectomy (26 or more nodes in the specimen) signifi-
cantly improved survival only in stage II and stage IIIa disease
(Siewert et al, 1993). This effect was, however, restricted to
patients with pN0 and pN1. There is strong evidence that pan-
creatico-splenectomy and splenectomy alone (and not radical
lymphadenectomy) are responsible for the increased morbidity and
mortality in the D2 arm of the MRC ST01 study (Cuschieri et al,
1996) and this observation is in agreement with the findings of the
Dutch trial (Bonenkamp et al, 1995). In the MRC ST01 trial, the
best long-term survival was obtained in the subgroup of patients
who underwent D2 resection without pancreatico-splenectomy.
Given the evidence that pancreatectomy is detrimental and should
be avoided unless necessary because of local involvement of the
pancreas during D2 resections, the question then remains of
whether the spleen should be preserved or removed during D2
resections for proximal gastric cancer. Two centres in the UK have
reported impressive results with low post-operative morbidity and
mortality and improved survival with spleen preserving D2 resec-
tions (Sue-Ling et al, 1993; Griffith, 1995). The argument against
splenic preservation is the incidence of lymph node metastases
along the distal splenic artery and splenic hilium (Japanese groups
10, 11) in patients with proximal tumours. Reported estimates for
deposits in these nodes vary from 15 to 27% (Fass and
Schumpelick, 1989; Mendes et al, 1994, 1995; Tsuburaya et al,
1995). In the present study 25% of patients with C and CM
tumours had involved splenic nodes. Some, possibly all, of the
splenic artery nodes can be removed with preservation of the
pancreas and spleen although this requires a high level of technical
skill, but the splenic hilar nodes cannot be removed safely without
a splenectomy. This is the remaining issue to be resolved in
surgery for proximal gastric cancer (excluding CMA lesions) –
radical lymphadenectomy with spleen preservation or splenec-
tomy. Aside from post-operative morbidity, the risks of fulmi-
nating post-splenectomy infections are well-documented, and the
possibility of increased growth of micrometastases in splenec-
tomized patients cannot be dismissed.
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